CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellit...
Phase 2
Kansas City, Missouri, United States and 14 other locations
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to pl...
Phase 3
Kansas City, Missouri, United States and 226 other locations
The goal of this clinical trial is to test a drug known as DFMO in people with Type 1 Diabetes (T1D). The main question\[s\] it aims to answ...
Phase 2
Kansas City, Kansas, United States and 6 other locations
Diabetic Retinopathy (DR) is a common eye condition caused by diabetes, where high blood sugar levels damage the blood vessels in t...
Phase 2, Phase 3
Lenexa, Kansas, United States and 33 other locations
This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple a...
Phase 1, Phase 2
Kansas City, Missouri, United States and 46 other locations
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus....
Phase 3
Lenexa, Kentucky, United States of America and 56 other locations
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to pl...
Phase 3
Kansas City, Missouri, United States and 94 other locations
Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term effic...
Phase 3
Kansas City, Kansas, United States and 134 other locations
control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes...
Phase 2
Kansas City, Missouri, United States and 29 other locations
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Phase 3
Kansas City, Missouri, United States and 186 other locations
Clinical trials
Research sites
Resources
Legal